What a Clinical Trial Agreement Contains

Part of Clinical Research Associate (CRA) Training: Start-Up, Contracts and Activation.

About 6 minutes. Free, in your language, no account needed.

Why this matters

You will never negotiate a contract. You will spend two years monitoring against one.

Most of what a site is expected to do operationally comes from the clinical trial agreement rather than from ICH or from law. Knowing which is which prevents you from imposing requirements that do not exist, and from missing ones that do.

What the agreement is

A clinical trial agreement, usually abbreviated to CTA, is a legally binding contract between the sponsor — or a CRO acting for the sponsor — and the research site, and sometimes the principal investigator separately.

It defines each party's responsibilities, the financial terms, the timelines, confidentiality, liability and insurance, rights over data and publications, and operational expectations such as record keeping and permitting audits.

The CTA must be fully executed before investigational product is shipped, before site activation is completed, and before any participant is enrolled. "In final review" is not executed.

Who is involved

The sponsor writes or approves the template, the budget guidelines, the payment structure, the indemnification and confidentiality language, and the data ownership terms.

The CRO, where one is involved, often handles negotiation, budget development, communication of sponsor requirements, execution tracking and amendments. As a CRA you usually feed information to the CRO's contracts team rather than dealing with the site's lawyers yourself.

The site or institution involves its contracts or legal office, its finance or grants office, the principal investigator, and often departmental administrators. Multi-step internal review is why sites move slowly, and understanding that helps you set expectations rather than getting frustrated.

The main sections

Scope of work. What the site is responsible for: conducting procedures per protocol and GCP, staffing including investigator oversight, recruitment expectations, data entry timelines, and permitting monitoring, audits and inspections.

Budget and payment terms. Per-visit fees, screen failure reimbursement, start-up costs, pharmacy and archiving fees, pass-through costs such as laboratory and imaging, payment schedules and invoicing, and any holdbacks or performance-linked payments.

Regulatory and compliance requirements. Compliance with GCP and applicable regulation, record retention timelines, audit and inspection cooperation, and reporting requirements for adverse events, deviations and safety updates.

Confidentiality and data privacy. How study data must be handled, limits on disclosure, responsibility for participant confidentiality, and secure storage requirements.

Indemnification and insurance. When and how the sponsor covers injury caused by the product or study procedures, what liabilities the site assumes, and required insurance levels.

Intellectual property and publication. Ownership of data and results, the sponsor's right to review manuscripts before publication, and restrictions on releasing preliminary results.

Termination and amendments. Grounds on which either party may end the agreement, the process for amending it, and obligations after termination including record retention.

How the contract reaches your daily work

Staffing levels. Contracts often specify investigator responsibilities, coordinator roles, required qualifications and time commitments. If the contract requires a full-time coordinator and the site has part-time cover, that is a contractual gap with operational consequences, and it is yours to document and escalate.

Timelines. Data entry within a stated number of days. Query resolution within a stated number of days. Serious adverse event reporting within a stated number of hours. These are contract and protocol terms, not ICH requirements, and you should describe them that way.

Record retention. Contracts state retention durations, which vary by region. Remember that ICH E6(R3) states no period in years; section 3.16.3 requires the sponsor to inform the site in writing. The contract is one place that instruction may live.

Monitoring and access. Contracts state that the site must permit monitoring visits, that the sponsor may audit, and that regulators may inspect. These clauses are what entitle you to source record access, including electronic health records. A site restricting your access may be in breach, and that is escalated immediately.

Payment questions. Sites ask CRAs about payment more than about almost anything else. Your role is narrow and important: verify that completed visits are properly documented in source and in the data system, because that is what payment is calculated from — then route the financial question to the project manager or contracts team.

Never interpret contract language and never discuss budget changes. That is not modesty; it is scope. An off-hand answer from a CRA has been treated as a commitment before.

In practice

At a VT-301 site, the coordinator tells Leah that two months of payments are missing and asks her to find out what has gone wrong.

Leah does the part that is hers. She checks the data system against the site's visit records and finds that eleven completed visits have not been marked complete in the electronic case report form, because the coordinator has been entering visit data but not applying the completion status.

She explains that payment is triggered from completed visit data, shows the coordinator the field, and routes the payment query to the project manager with a note about what she found.

She does not read the payment schedule aloud, and she does not estimate what the site is owed.

The visits are completed in the system, the payment issue resolves, and the site's data entry improves for an unrelated reason: the coordinator now understands what the completion status does.

Key takeaways